<p>STAAR Surgical（纳斯达克股票代码：STAA - 获取免费报告）在周六发布给投资者的研究报告中，被华尔街 Zen 的股票分析师从 “持有” 评级上调至 “买入” 评级。</p>
<p>获取 <strong>STAAR Surgical</strong> 的提醒：</p>
<ul>
<li>4 只内部人士显著买入的股票</li>
</ul>
<p>其他分析师最近也发布了关于该股票的研究报告。Stifel Nicolaus 将 STAAR Surgical 的目标价从 18.00 美元上调至 31.00 美元，并在周四的报告中给予该股票 “持有” 评级。Canaccord Genuity Group 将 STAAR Surgical 的目标价从 27.00 美元上调至 32.00 美元，并在周四的报告中给予该股票 “买入” 评级。摩根士丹利在 1 月 16 日的报告中开始覆盖 STAAR Surgical 的股票，给予 “减持” 评级和 13.00 美元的目标价。Piper Sandler 将 STAAR Surgical 的目标价从 16.00 美元上调至 33.00 美元，并在周四的报告中给予该股票 “中性” 评级。最后，Wedbush 将 STAAR Surgical 的评级从 “中性” 上调至 “跑赢大盘”，并在周四的报告中将该股票的目标价从 26.00 美元上调至 40.00 美元。三位分析师给予该股票 “买入” 评级，六位分析师给予 “持有” 评级，二位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 27.81 美元。</p>
<p><strong>查看我们关于 STAAR Surgical 的最新研究报告</strong></p>
<h2>STAAR Surgical 股票上涨 0.2%</h2>
<ul>
<li>随着 2024 年美国前景改善，Star Surgical 表现亮眼</li>
</ul>
<p>周五，纳斯达克 STAA 的股票开盘价为 32.07 美元。该公司的市值为 16 亿美元，市盈率为-74.58，贝塔系数为 1.20。STAAR Surgical 的 52 周最低价为 15.59 美元，52 周最高价为 35.87 美元。该公司的 50 日移动平均价格为 22.74 美元，200 日移动平均价格为 22.65 美元。公司的速动比率为 3.74，流动比率为 5.12，债务与股本比率为 0.09。</p>
<p>STAAR Surgical（纳斯达克股票代码：STAA - 获取免费报告）最后一次发布季度财报是在 5 月 13 日，医疗器械供应商报告该季度每股收益为 0.10 美元，超出分析师共识预期的 0.05 美元。该公司该季度的收入为 9352 万美元，而共识预期为 7872 万美元。STAAR Surgical 的净利润率为-7.24%，股本回报率为 3.31%。该公司的收入同比增长 119.6%。在去年同期，该公司每股收益为-1.10 美元。股票研究分析师预计 STAAR Surgical 在当前财年将发布-0.03 美元的每股收益。</p>
<h2>STAAR Surgical 的内部交易</h2>
<p>在其他 STAAR Surgical 的新闻中，董事 Broadwood Partners, L.P.在 3 月 13 日的交易中购买了 316,017 股该公司的股票。该股票的平均购买价格为每股 18.61 美元，总交易额为 5,881,076.37 美元。交易完成后，该董事在公司持有 16,123,842 股，估值约为 300,064,699.62 美元。此次交易使其持股增加了 2.00%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。在过去的九十天里，内部人士共购买了 670,213 股公司股票，价值为 12,266,249 美元。内部人士持有公司 39.90% 的股份。</p>
<h2>对 STAAR Surgical 的对冲基金看法</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了在 STAA 的持股。凯通国际资产管理有限公司在第三季度将其在 STAAR Surgical 的持股增加了 2,605.1%。凯通国际资产管理有限公司现在持有 1,055 股医疗器械供应商的股票，价值 28,000 美元，此前在上个季度又购买了 1,016 股。Ascentis Independent Advisors 在第一季度获得了 STAAR Surgical 的新头寸，估值约为 77,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 STAAR Surgical 的持股增加了 375.0%。Tower Research Capital LLC TRC 现在持有 5,919 股医疗器械供应商的股票，价值 99,000 美元，此前在上个季度又购买了 4,673 股。拉塞尔投资集团有限公司在第三季度将其在 STAAR Surgical 的持股增加了 9,928.9%。拉塞尔投资集团有限公司现在持有 4,513 股医疗器械供应商的股票，价值 121,000 美元，此前在上个季度又购买了 4,468 股。最后，Wolverine Asset Management LLC 在第三季度获得了 STAAR Surgical 的新头寸，估值约为 199,000 美元。机构投资者和对冲基金持有公司 96.70% 的股份。</p>
<h2>更多 STAAR Surgical 新闻</h2>
<p>以下是本周影响 STAAR Surgical 的主要新闻故事：</p>
<ul>
<li>积极情绪：STAAR Surgical 超过了第一季度的盈利和收入预期，业务实现盈利，并显示出强劲的同比改善。Staar Surgical (STAA) 超过第一季度盈利和收入预期</li>
<li>积极情绪：Wedbush 将 STAA 升级为 <strong>跑赢大盘</strong>，并将其目标价提高至 40 美元，理由是与中国复苏相关的前景改善。STAAR Surgical 被 Wedbush 升级</li>
<li>积极情绪：瑞穗证券对该股票的看法也变得更加积极，目标价上调，反映出更好的盈利动能和前景预期。瑞穗证券对 STAAR Surgical 股票价格发布积极预测</li>
<li>积极情绪：关于财报电话会议的评论强调了中国市场的强劲、成本控制和库存稳定作为业务转机的驱动因素。Staar Surgical 在中国市场强劲的背景下发出明显的转机信号</li>
<li>中性情绪：富国银行将其目标价提高至 25 美元，但维持 <strong>持平</strong> 评级，尽管近期反弹，仍显示出一些谨慎。STAAR Surgical 的目标价被富国银行上调</li>
<li>消极情绪：一些分析师仍然认为 STAAR Surgical 2026 年的前景有限，新的风险披露增加了对未来表现和估值的不确定性。Staar Surgical 面临加剧的不确定性</li>
</ul>
<h2>关于 STAAR Surgical</h2>
<p>(获取免费报告)</p>
<p>STAAR Surgical Company 及其子公司设计、开发、制造、营销和销售可植入眼内镜片及其伴随的输送系统，以将镜片植入眼内。该公司提供可植入的 Collamer 镜片产品系列 (ICLs)，用于治疗视觉障碍，如近视、远视、散光和老花眼。它将产品销售给医疗保健提供者，包括眼科外科医生、视力和外科中心、医院、政府机构和分销商，产品主要由眼科医生使用。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 STAAR Surgical</li>
<li>Viking 股价创历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家未盈利的矿业公司值得关注</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 STAAR Surgical 吗？</h2>
<p>在考虑 STAAR Surgical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 STAAR Surgical 并不在名单上。</p>
<p>虽然 STAAR Surgical 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

达视光学

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>华尔街禅将 STAAR Surgical（纳斯达克代码：STAA）的评级从 “持有” 上调至 “买入”。其他分析师也提高了他们的目标价，Stifel Nicolaus 将其从 18 美元上调至 31 美元，Canaccord Genuity 则从 27 美元上调至 32 美元。该股票开盘价为 32.07 美元，市值为 16 亿美元。最近的财报显示，收入同比增长 119.6%，每股收益为 0.10 美元，超出预期</p>

<p>STAAR Surgical (NASDAQ:STAA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued to investors on Saturday.</p>
<div class="lb-trans"><p>STAAR Surgical（纳斯达克股票代码：STAA - 获取免费报告）在周六发布给投资者的研究报告中，被华尔街 Zen 的股票分析师从 “持有” 评级上调至 “买入” 评级。</p>
</div><p>Get <strong>STAAR Surgical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>STAAR Surgical</strong> 的提醒：</p>
</div><ul>
<li>Top 4 Stocks With Notable Insider Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只内部人士显著买入的股票</li>
</ul>
</div><p>Other analysts also recently issued research reports about the stock. Stifel Nicolaus boosted their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a &#34;hold&#34; rating in a report on Thursday. Canaccord Genuity Group boosted their price objective on shares of STAAR Surgical from $27.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday. Morgan Stanley started coverage on shares of STAAR Surgical in a report on Friday, January 16th. They set an &#34;underweight&#34; rating and a $13.00 price objective on the stock. Piper Sandler boosted their price objective on shares of STAAR Surgical from $16.00 to $33.00 and gave the stock a &#34;neutral&#34; rating in a report on Thursday. Finally, Wedbush raised shares of STAAR Surgical from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and boosted their price objective for the stock from $26.00 to $40.00 in a report on Thursday. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and a consensus target price of $27.81.</p>
<div class="lb-trans"><p>其他分析师最近也发布了关于该股票的研究报告。Stifel Nicolaus 将 STAAR Surgical 的目标价从 18.00 美元上调至 31.00 美元，并在周四的报告中给予该股票 “持有” 评级。Canaccord Genuity Group 将 STAAR Surgical 的目标价从 27.00 美元上调至 32.00 美元，并在周四的报告中给予该股票 “买入” 评级。摩根士丹利在 1 月 16 日的报告中开始覆盖 STAAR Surgical 的股票，给予 “减持” 评级和 13.00 美元的目标价。Piper Sandler 将 STAAR Surgical 的目标价从 16.00 美元上调至 33.00 美元，并在周四的报告中给予该股票 “中性” 评级。最后，Wedbush 将 STAAR Surgical 的评级从 “中性” 上调至 “跑赢大盘”，并在周四的报告中将该股票的目标价从 26.00 美元上调至 40.00 美元。三位分析师给予该股票 “买入” 评级，六位分析师给予 “持有” 评级，二位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，共识目标价为 27.81 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on STAAR Surgical</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 STAAR Surgical 的最新研究报告</strong></p>
</div><h2>STAAR Surgical Stock Up 0.2%</h2>
<div class="lb-trans"><h2>STAAR Surgical 股票上涨 0.2%</h2>
</div><ul>
<li>Star Surgical Shines as U.S. Outlook Improves for 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>随着 2024 年美国前景改善，Star Surgical 表现亮眼</li>
</ul>
</div><p>Shares of NASDAQ STAA opened at $32.07 on Friday. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -74.58 and a beta of 1.20. STAAR Surgical has a 52 week low of $15.59 and a 52 week high of $35.87. The firm has a 50-day moving average price of $22.74 and a 200 day moving average price of $22.65. The company has a quick ratio of 3.74, a current ratio of 5.12 and a debt-to-equity ratio of 0.09.</p>
<div class="lb-trans"><p>周五，纳斯达克 STAA 的股票开盘价为 32.07 美元。该公司的市值为 16 亿美元，市盈率为-74.58，贝塔系数为 1.20。STAAR Surgical 的 52 周最低价为 15.59 美元，52 周最高价为 35.87 美元。该公司的 50 日移动平均价格为 22.74 美元，200 日移动平均价格为 22.65 美元。公司的速动比率为 3.74，流动比率为 5.12，债务与股本比率为 0.09。</p>
</div><p>STAAR Surgical (NASDAQ:STAA - Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.05. The firm had revenue of $93.52 million for the quarter, compared to the consensus estimate of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The firm's revenue was up 119.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.10) earnings per share. Equities research analysts anticipate that STAAR Surgical will post -0.03 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>STAAR Surgical（纳斯达克股票代码：STAA - 获取免费报告）最后一次发布季度财报是在 5 月 13 日，医疗器械供应商报告该季度每股收益为 0.10 美元，超出分析师共识预期的 0.05 美元。该公司该季度的收入为 9352 万美元，而共识预期为 7872 万美元。STAAR Surgical 的净利润率为-7.24%，股本回报率为 3.31%。该公司的收入同比增长 119.6%。在去年同期，该公司每股收益为-1.10 美元。股票研究分析师预计 STAAR Surgical 在当前财年将发布-0.03 美元的每股收益。</p>
</div><h2>Insider Transactions at STAAR Surgical</h2>
<div class="lb-trans"><h2>STAAR Surgical 的内部交易</h2>
</div><p>In other STAAR Surgical news, Director Broadwood Partners, L.P. bought 316,017 shares of the business's stock in a transaction on Friday, March 13th. The stock was bought at an average price of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the transaction, the director owned 16,123,842 shares in the company, valued at approximately $300,064,699.62. The trade was a 2.00% increase in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 670,213 shares of company stock worth $12,266,249 in the last ninety days. Insiders own 39.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 STAAR Surgical 的新闻中，董事 Broadwood Partners, L.P.在 3 月 13 日的交易中购买了 316,017 股该公司的股票。该股票的平均购买价格为每股 18.61 美元，总交易额为 5,881,076.37 美元。交易完成后，该董事在公司持有 16,123,842 股，估值约为 300,064,699.62 美元。此次交易使其持股增加了 2.00%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接获取。在过去的九十天里，内部人士共购买了 670,213 股公司股票，价值为 12,266,249 美元。内部人士持有公司 39.90% 的股份。</p>
</div><h2>Hedge Funds Weigh In On STAAR Surgical</h2>
<div class="lb-trans"><h2>对 STAAR Surgical 的对冲基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STAA. Caitong International Asset Management Co. Ltd raised its position in STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 1,016 shares during the last quarter. Ascentis Independent Advisors acquired a new position in shares of STAAR Surgical in the first quarter valued at approximately $77,000. Tower Research Capital LLC TRC raised its position in shares of STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 4,673 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of STAAR Surgical by 9,928.9% in the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier's stock valued at $121,000 after buying an additional 4,468 shares during the last quarter. Finally, Wolverine Asset Management LLC acquired a new position in shares of STAAR Surgical in the third quarter valued at approximately $199,000. Institutional investors and hedge funds own 96.70% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了在 STAA 的持股。凯通国际资产管理有限公司在第三季度将其在 STAAR Surgical 的持股增加了 2,605.1%。凯通国际资产管理有限公司现在持有 1,055 股医疗器械供应商的股票，价值 28,000 美元，此前在上个季度又购买了 1,016 股。Ascentis Independent Advisors 在第一季度获得了 STAAR Surgical 的新头寸，估值约为 77,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 STAAR Surgical 的持股增加了 375.0%。Tower Research Capital LLC TRC 现在持有 5,919 股医疗器械供应商的股票，价值 99,000 美元，此前在上个季度又购买了 4,673 股。拉塞尔投资集团有限公司在第三季度将其在 STAAR Surgical 的持股增加了 9,928.9%。拉塞尔投资集团有限公司现在持有 4,513 股医疗器械供应商的股票，价值 121,000 美元，此前在上个季度又购买了 4,468 股。最后，Wolverine Asset Management LLC 在第三季度获得了 STAAR Surgical 的新头寸，估值约为 199,000 美元。机构投资者和对冲基金持有公司 96.70% 的股份。</p>
</div><h2>More STAAR Surgical News</h2>
<div class="lb-trans"><h2>更多 STAAR Surgical 新闻</h2>
</div><p>Here are the key news stories impacting STAAR Surgical this week:</p>
<div class="lb-trans"><p>以下是本周影响 STAAR Surgical 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: STAAR Surgical beat Q1 earnings and revenue expectations, with the business swinging to a profit and showing strong year-over-year improvement. Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates</li>
<li>Positive Sentiment: Wedbush upgraded STAA to <strong>Outperform</strong> and lifted its price target to $40, citing improving prospects tied to a China recovery. STAAR Surgical was upgraded by Wedbush</li>
<li>Positive Sentiment: Mizuho also turned more constructive on the stock with a higher price target, reflecting better earnings momentum and outlook expectations. Mizuho Issues Positive Forecast for STAAR Surgical Stock Price</li>
<li>Positive Sentiment: Commentary around the earnings call highlighted China strength, cost discipline, and stabilizing inventory as drivers of the turnaround. Staar Surgical Signals Sharp Turnaround Amid China Strength</li>
<li>Neutral Sentiment: Wells Fargo raised its price target to $25 but kept an <strong>Equal Weight</strong> rating, signaling some caution despite the recent rally. STAAR Surgical had its price target raised by Wells Fargo</li>
<li>Negative Sentiment: Some analysts still see limited visibility into STAAR Surgical’s 2026 outlook, and a new risk disclosure added to uncertainty around future performance and valuation. Staar Surgical Faces Heightened Uncertainty</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：STAAR Surgical 超过了第一季度的盈利和收入预期，业务实现盈利，并显示出强劲的同比改善。Staar Surgical (STAA) 超过第一季度盈利和收入预期</li>
<li>积极情绪：Wedbush 将 STAA 升级为 <strong>跑赢大盘</strong>，并将其目标价提高至 40 美元，理由是与中国复苏相关的前景改善。STAAR Surgical 被 Wedbush 升级</li>
<li>积极情绪：瑞穗证券对该股票的看法也变得更加积极，目标价上调，反映出更好的盈利动能和前景预期。瑞穗证券对 STAAR Surgical 股票价格发布积极预测</li>
<li>积极情绪：关于财报电话会议的评论强调了中国市场的强劲、成本控制和库存稳定作为业务转机的驱动因素。Staar Surgical 在中国市场强劲的背景下发出明显的转机信号</li>
<li>中性情绪：富国银行将其目标价提高至 25 美元，但维持 <strong>持平</strong> 评级，尽管近期反弹，仍显示出一些谨慎。STAAR Surgical 的目标价被富国银行上调</li>
<li>消极情绪：一些分析师仍然认为 STAAR Surgical 2026 年的前景有限，新的风险披露增加了对未来表现和估值的不确定性。Staar Surgical 面临加剧的不确定性</li>
</ul>
</div><h2>About STAAR Surgical</h2>
<div class="lb-trans"><h2>关于 STAAR Surgical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.</p>
<div class="lb-trans"><p>STAAR Surgical Company 及其子公司设计、开发、制造、营销和销售可植入眼内镜片及其伴随的输送系统，以将镜片植入眼内。该公司提供可植入的 Collamer 镜片产品系列 (ICLs)，用于治疗视觉障碍，如近视、远视、散光和老花眼。它将产品销售给医疗保健提供者，包括眼科外科医生、视力和外科中心、医院、政府机构和分销商，产品主要由眼科医生使用。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than STAAR Surgical</li>
<li>Viking Sails to All-Time Highs—Fundamentals Signal More to Come</li>
<li>Datavalut Gains Traction: 5 Reasons to Sell Now</li>
<li>TMC Stock: Why This Pre-Revenue Miner Is Worth Watching</li>
<li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 STAAR Surgical</li>
<li>Viking 股价创历史新高——基本面信号显示未来还有更多</li>
<li>Datavalut 获得关注：现在卖出的五个理由</li>
<li>TMC 股票：为什么这家未盈利的矿业公司值得关注</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=STAA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in STAAR Surgical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 STAAR Surgical 吗？</h2>
</div><p>Before you consider STAAR Surgical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 STAAR Surgical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而 STAAR Surgical 并不在名单上。</p>
</div><p>While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 STAAR Surgical 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

STAAR Surgical (NASDAQ:STAA) Upgraded at Wall Street Zen

Market Beat

摩根士丹利

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

达视光学（NASDAQ:STAA）在 Wall Street Zen 获得评级上调